NASDAQ:GBIO Generation Bio (GBIO) Stock Price, News & Analysis $6.45 +0.17 (+2.71%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$6.54 +0.09 (+1.32%) As of 08/22/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Generation Bio Stock (NASDAQ:GBIO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Generation Bio alerts:Sign Up Key Stats Today's Range$6.28▼$6.5550-Day Range$3.00▼$6.6652-Week Range$3.00▼$29.40Volume78,248 shsAverage Volume814,285 shsMarket Capitalization$43.44 millionP/E RatioN/ADividend YieldN/APrice Target$10.67Consensus RatingModerate Buy Company Overview Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. Read More Generation Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreGBIO MarketRank™: Generation Bio scored higher than 64% of companies evaluated by MarketBeat, and ranked 381st out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingGeneration Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageGeneration Bio has only been the subject of 3 research reports in the past 90 days.Read more about Generation Bio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Generation Bio are expected to grow in the coming year, from ($1.75) to ($0.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Generation Bio is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Generation Bio is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeneration Bio has a P/B Ratio of 0.80. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Generation Bio's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.15% of the float of Generation Bio has been sold short.Short Interest Ratio / Days to CoverGeneration Bio has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Generation Bio has recently increased by 20.74%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGeneration Bio does not currently pay a dividend.Dividend GrowthGeneration Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.15% of the float of Generation Bio has been sold short.Short Interest Ratio / Days to CoverGeneration Bio has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Generation Bio has recently increased by 20.74%, indicating that investor sentiment is decreasing significantly. News and Social Media1.5 / 5News Sentiment-0.25 News SentimentGeneration Bio has a news sentiment score of -0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Generation Bio this week, compared to 1 article on an average week.Search Interest8 people have searched for GBIO on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Generation Bio insiders have not sold or bought any company stock.Percentage Held by Insiders21.80% of the stock of Generation Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.22% of the stock of Generation Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Generation Bio's insider trading history. Receive GBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Generation Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address GBIO Stock News HeadlinesGeneration Bio price target raised to $10 from $9 at CanaccordAugust 19, 2025 | msn.comGeneration Bio (NASDAQ:GBIO) Stock Price Expected to Rise, Canaccord Genuity Group Analyst SaysAugust 19, 2025 | americanbankingnews.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.August 23 at 2:00 AM | American Alternative (Ad)Wedbush Brokers Reduce Earnings Estimates for Generation BioAugust 16, 2025 | americanbankingnews.comGeneration Bio's (GBIO) "Buy" Rating Reiterated at Needham & Company LLCAugust 15, 2025 | americanbankingnews.comGeneration Bio Inc. (GBIO) Stock Price Today - WSJAugust 14, 2025 | wsj.comGeneration Bio soars as it explores strategic alternativesAugust 14, 2025 | msn.comWedbush Downgrades Generation Bio (GBIO)August 14, 2025 | msn.comSee More Headlines GBIO Stock Analysis - Frequently Asked Questions How have GBIO shares performed this year? Generation Bio's stock was trading at $10.60 at the beginning of 2025. Since then, GBIO shares have decreased by 39.2% and is now trading at $6.45. How were Generation Bio's earnings last quarter? Generation Bio Co. (NASDAQ:GBIO) released its earnings results on Tuesday, August, 12th. The company reported ($3.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.80) by $0.32. The business had revenue of $0.77 million for the quarter, compared to analysts' expectations of $2.51 million. Generation Bio had a negative net margin of 341.12% and a negative trailing twelve-month return on equity of 91.07%. When did Generation Bio's stock split? Shares of Generation Bio reverse split before market open on Tuesday, July 22nd 2025.The 1-10 reverse split was announced on Friday, July 18th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 21st 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Generation Bio IPO? Generation Bio (GBIO) raised $126 million in an initial public offering on Friday, June 12th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Generation Bio's major shareholders? Top institutional investors of Generation Bio include Bank of America Corp DE (12.94%), Militia Capital Partners LP (8.05%), Geode Capital Management LLC (7.39%) and Y Intercept Hong Kong Ltd (2.21%). Insiders that own company stock include Phillip Samayoa, Antoinette Paone and Dannielle Appelhans. View institutional ownership trends. How do I buy shares of Generation Bio? Shares of GBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Generation Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Generation Bio investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Visa (V) and Home Depot (HD). Company Calendar Last Earnings8/12/2025Today8/23/2025Next Earnings (Estimated)11/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GBIO CIK1733294 Webgenerationbio.com Phone617-655-7500FaxN/AEmployees150Year FoundedN/APrice Target and Rating Average Price Target for Generation Bio$10.67 High Price Target$15.00 Low Price Target$7.00 Potential Upside/Downside+65.4%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($10.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$131.67 million Net Margins-341.12% Pretax Margin-341.12% Return on Equity-91.07% Return on Assets-33.65% Debt Debt-to-Equity RatioN/A Current Ratio7.51 Quick Ratio7.51 Sales & Book Value Annual Sales$21.23 million Price / Sales2.05 Cash FlowN/A Price / Cash FlowN/A Book Value$8.03 per share Price / Book0.80Miscellaneous Outstanding Shares6,735,000Free Float5,267,000Market Cap$43.44 million OptionableOptionable Beta2.67 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:GBIO) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Generation Bio Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Generation Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.